Global HR+HER2- Breast Cancer Market Research Report 2022
Table of Contents1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global HR+HER2- Breast Cancer Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 CDK4/6 Inhibitors
1.2.3 PARP Inhibitors
1.2.4 PI3K Inhibitor
1.2.5 Others
1.3 Market by Application
1.3.1 Global HR+HER2- Breast Cancer Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Cancer Center
1.3.4 Medical Research and Academic Institutions
1.3.5 Ambulatory Surgical Centers
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global HR+HER2- Breast Cancer Market Perspective (2017-2028)
2.2 HR+HER2- Breast Cancer Growth Trends by Region
2.2.1 HR+HER2- Breast Cancer Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 HR+HER2- Breast Cancer Historic Market Size by Region (2017-2022)
2.2.3 HR+HER2- Breast Cancer Forecasted Market Size by Region (2023-2028)
2.3 HR+HER2- Breast Cancer Market Dynamics
2.3.1 HR+HER2- Breast Cancer Industry Trends
2.3.2 HR+HER2- Breast Cancer Market Drivers
2.3.3 HR+HER2- Breast Cancer Market Challenges
2.3.4 HR+HER2- Breast Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top HR+HER2- Breast Cancer Players by Revenue
3.1.1 Global Top HR+HER2- Breast Cancer Players by Revenue (2017-2022)
3.1.2 Global HR+HER2- Breast Cancer Revenue Market Share by Players (2017-2022)
3.2 Global HR+HER2- Breast Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by HR+HER2- Breast Cancer Revenue
3.4 Global HR+HER2- Breast Cancer Market Concentration Ratio
3.4.1 Global HR+HER2- Breast Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by HR+HER2- Breast Cancer Revenue in 2021
3.5 HR+HER2- Breast Cancer Key Players Head office and Area Served
3.6 Key Players HR+HER2- Breast Cancer Product Solution and Service
3.7 Date of Enter into HR+HER2- Breast Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans
4 HR+HER2- Breast Cancer Breakdown Data by Type
4.1 Global HR+HER2- Breast Cancer Historic Market Size by Type (2017-2022)
4.2 Global HR+HER2- Breast Cancer Forecasted Market Size by Type (2023-2028)
5 HR+HER2- Breast Cancer Breakdown Data by Application
5.1 Global HR+HER2- Breast Cancer Historic Market Size by Application (2017-2022)
5.2 Global HR+HER2- Breast Cancer Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America HR+HER2- Breast Cancer Market Size (2017-2028)
6.2 North America HR+HER2- Breast Cancer Market Size by Country (2017-2022)
6.3 North America HR+HER2- Breast Cancer Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe HR+HER2- Breast Cancer Market Size (2017-2028)
7.2 Europe HR+HER2- Breast Cancer Market Size by Country (2017-2022)
7.3 Europe HR+HER2- Breast Cancer Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific HR+HER2- Breast Cancer Market Size (2017-2028)
8.2 Asia-Pacific HR+HER2- Breast Cancer Market Size by Country (2017-2022)
8.3 Asia-Pacific HR+HER2- Breast Cancer Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America HR+HER2- Breast Cancer Market Size (2017-2028)
9.2 Latin America HR+HER2- Breast Cancer Market Size by Country (2017-2022)
9.3 Latin America HR+HER2- Breast Cancer Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa HR+HER2- Breast Cancer Market Size (2017-2028)
10.2 Middle East & Africa HR+HER2- Breast Cancer Market Size by Country (2017-2022)
10.3 Middle East & Africa HR+HER2- Breast Cancer Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Jiangsu HengRui Medicine
11.1.1 Jiangsu HengRui Medicine Company Detail
11.1.2 Jiangsu HengRui Medicine Business Overview
11.1.3 Jiangsu HengRui Medicine HR+HER2- Breast Cancer Introduction
11.1.4 Jiangsu HengRui Medicine Revenue in HR+HER2- Breast Cancer Business (2017-2022)
11.1.5 Jiangsu HengRui Medicine Recent Development
11.2 Odonate Therapeutics
11.2.1 Odonate Therapeutics Company Detail
11.2.2 Odonate Therapeutics Business Overview
11.2.3 Odonate Therapeutics HR+HER2- Breast Cancer Introduction
11.2.4 Odonate Therapeutics Revenue in HR+HER2- Breast Cancer Business (2017-2022)
11.2.5 Odonate Therapeutics Recent Development
11.3 Radius Pharmaceuticals
11.3.1 Radius Pharmaceuticals Company Detail
11.3.2 Radius Pharmaceuticals Business Overview
11.3.3 Radius Pharmaceuticals HR+HER2- Breast Cancer Introduction
11.3.4 Radius Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2017-2022)
11.3.5 Radius Pharmaceuticals Recent Development
11.4 Immunomedics
11.4.1 Immunomedics Company Detail
11.4.2 Immunomedics Business Overview
11.4.3 Immunomedics HR+HER2- Breast Cancer Introduction
11.4.4 Immunomedics Revenue in HR+HER2- Breast Cancer Business (2017-2022)
11.4.5 Immunomedics Recent Development
11.5 Roche Group
11.5.1 Roche Group Company Detail
11.5.2 Roche Group Business Overview
11.5.3 Roche Group HR+HER2- Breast Cancer Introduction
11.5.4 Roche Group Revenue in HR+HER2- Breast Cancer Business (2017-2022)
11.5.5 Roche Group Recent Development
11.6 Syndax Pharmaceuticals
11.6.1 Syndax Pharmaceuticals Company Detail
11.6.2 Syndax Pharmaceuticals Business Overview
11.6.3 Syndax Pharmaceuticals HR+HER2- Breast Cancer Introduction
11.6.4 Syndax Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2017-2022)
11.6.5 Syndax Pharmaceuticals Recent Development
11.7 Merck
11.7.1 Merck Company Detail
11.7.2 Merck Business Overview
11.7.3 Merck HR+HER2- Breast Cancer Introduction
11.7.4 Merck Revenue in HR+HER2- Breast Cancer Business (2017-2022)
11.7.5 Merck Recent Development
11.8 Eagle Pharmaceuticals
11.8.1 Eagle Pharmaceuticals Company Detail
11.8.2 Eagle Pharmaceuticals Business Overview
11.8.3 Eagle Pharmaceuticals HR+HER2- Breast Cancer Introduction
11.8.4 Eagle Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2017-2022)
11.8.5 Eagle Pharmaceuticals Recent Development
11.9 Merrimack Pharmaceuticals
11.9.1 Merrimack Pharmaceuticals Company Detail
11.9.2 Merrimack Pharmaceuticals Business Overview
11.9.3 Merrimack Pharmaceuticals HR+HER2- Breast Cancer Introduction
11.9.4 Merrimack Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2017-2022)
11.9.5 Merrimack Pharmaceuticals Recent Development
11.10 GlaxoSmithKline
11.10.1 GlaxoSmithKline Company Detail
11.10.2 GlaxoSmithKline Business Overview
11.10.3 GlaxoSmithKline HR+HER2- Breast Cancer Introduction
11.10.4 GlaxoSmithKline Revenue in HR+HER2- Breast Cancer Business (2017-2022)
11.10.5 GlaxoSmithKline Recent Development
11.11 Millennium Pharmaceuticals
11.11.1 Millennium Pharmaceuticals Company Detail
11.11.2 Millennium Pharmaceuticals Business Overview
11.11.3 Millennium Pharmaceuticals HR+HER2- Breast Cancer Introduction
11.11.4 Millennium Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2017-2022)
11.11.5 Millennium Pharmaceuticals Recent Development
11.12 Bayer
11.12.1 Bayer Company Detail
11.12.2 Bayer Business Overview
11.12.3 Bayer HR+HER2- Breast Cancer Introduction
11.12.4 Bayer Revenue in HR+HER2- Breast Cancer Business (2017-2022)
11.12.5 Bayer Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesTable 1. Global HR+HER2- Breast Cancer Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of CDK4/6 Inhibitors
Table 3. Key Players of PARP Inhibitors
Table 4. Key Players of PI3K Inhibitor
Table 5. Key Players of Others
Table 6. Global HR+HER2- Breast Cancer Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 7. Global HR+HER2- Breast Cancer Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 8. Global HR+HER2- Breast Cancer Market Size by Region (2017-2022) & (US$ Million)
Table 9. Global HR+HER2- Breast Cancer Market Share by Region (2017-2022)
Table 10. Global HR+HER2- Breast Cancer Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 11. Global HR+HER2- Breast Cancer Market Share by Region (2023-2028)
Table 12. HR+HER2- Breast Cancer Market Trends
Table 13. HR+HER2- Breast Cancer Market Drivers
Table 14. HR+HER2- Breast Cancer Market Challenges
Table 15. HR+HER2- Breast Cancer Market Restraints
Table 16. Global HR+HER2- Breast Cancer Revenue by Players (2017-2022) & (US$ Million)
Table 17. Global HR+HER2- Breast Cancer Market Share by Players (2017-2022)
Table 18. Global Top HR+HER2- Breast Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HR+HER2- Breast Cancer as of 2021)
Table 19. Ranking of Global Top HR+HER2- Breast Cancer Companies by Revenue (US$ Million) in 2021
Table 20. Global 5 Largest Players Market Share by HR+HER2- Breast Cancer Revenue (CR5 and HHI) & (2017-2022)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players HR+HER2- Breast Cancer Product Solution and Service
Table 23. Date of Enter into HR+HER2- Breast Cancer Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global HR+HER2- Breast Cancer Market Size by Type (2017-2022) & (US$ Million)
Table 26. Global HR+HER2- Breast Cancer Revenue Market Share by Type (2017-2022)
Table 27. Global HR+HER2- Breast Cancer Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 28. Global HR+HER2- Breast Cancer Revenue Market Share by Type (2023-2028)
Table 29. Global HR+HER2- Breast Cancer Market Size by Application (2017-2022) & (US$ Million)
Table 30. Global HR+HER2- Breast Cancer Revenue Market Share by Application (2017-2022)
Table 31. Global HR+HER2- Breast Cancer Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 32. Global HR+HER2- Breast Cancer Revenue Market Share by Application (2023-2028)
Table 33. North America HR+HER2- Breast Cancer Market Size by Country (2017-2022) & (US$ Million)
Table 34. North America HR+HER2- Breast Cancer Market Size by Country (2023-2028) & (US$ Million)
Table 35. Europe HR+HER2- Breast Cancer Market Size by Country (2017-2022) & (US$ Million)
Table 36. Europe HR+HER2- Breast Cancer Market Size by Country (2023-2028) & (US$ Million)
Table 37. Asia-Pacific HR+HER2- Breast Cancer Market Size by Region (2017-2022) & (US$ Million)
Table 38. Asia-Pacific HR+HER2- Breast Cancer Market Size by Region (2023-2028) & (US$ Million)
Table 39. Latin America HR+HER2- Breast Cancer Market Size by Country (2017-2022) & (US$ Million)
Table 40. Latin America HR+HER2- Breast Cancer Market Size by Country (2023-2028) & (US$ Million)
Table 41. Middle East & Africa HR+HER2- Breast Cancer Market Size by Country (2017-2022) & (US$ Million)
Table 42. Middle East & Africa HR+HER2- Breast Cancer Market Size by Country (2023-2028) & (US$ Million)
Table 43. Jiangsu HengRui Medicine Company Detail
Table 44. Jiangsu HengRui Medicine Business Overview
Table 45. Jiangsu HengRui Medicine HR+HER2- Breast Cancer Product
Table 46. Jiangsu HengRui Medicine Revenue in HR+HER2- Breast Cancer Business (2017-2022) & (US$ Million)
Table 47. Jiangsu HengRui Medicine Recent Development
Table 48. Odonate Therapeutics Company Detail
Table 49. Odonate Therapeutics Business Overview
Table 50. Odonate Therapeutics HR+HER2- Breast Cancer Product
Table 51. Odonate Therapeutics Revenue in HR+HER2- Breast Cancer Business (2017-2022) & (US$ Million)
Table 52. Odonate Therapeutics Recent Development
Table 53. Radius Pharmaceuticals Company Detail
Table 54. Radius Pharmaceuticals Business Overview
Table 55. Radius Pharmaceuticals HR+HER2- Breast Cancer Product
Table 56. Radius Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2017-2022) & (US$ Million)
Table 57. Radius Pharmaceuticals Recent Development
Table 58. Immunomedics Company Detail
Table 59. Immunomedics Business Overview
Table 60. Immunomedics HR+HER2- Breast Cancer Product
Table 61. Immunomedics Revenue in HR+HER2- Breast Cancer Business (2017-2022) & (US$ Million)
Table 62. Immunomedics Recent Development
Table 63. Roche Group Company Detail
Table 64. Roche Group Business Overview
Table 65. Roche Group HR+HER2- Breast Cancer Product
Table 66. Roche Group Revenue in HR+HER2- Breast Cancer Business (2017-2022) & (US$ Million)
Table 67. Roche Group Recent Development
Table 68. Syndax Pharmaceuticals Company Detail
Table 69. Syndax Pharmaceuticals Business Overview
Table 70. Syndax Pharmaceuticals HR+HER2- Breast Cancer Product
Table 71. Syndax Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2017-2022) & (US$ Million)
Table 72. Syndax Pharmaceuticals Recent Development
Table 73. Merck Company Detail
Table 74. Merck Business Overview
Table 75. Merck HR+HER2- Breast Cancer Product
Table 76. Merck Revenue in HR+HER2- Breast Cancer Business (2017-2022) & (US$ Million)
Table 77. Merck Recent Development
Table 78. Eagle Pharmaceuticals Company Detail
Table 79. Eagle Pharmaceuticals Business Overview
Table 80. Eagle Pharmaceuticals HR+HER2- Breast Cancer Product
Table 81. Eagle Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2017-2022) & (US$ Million)
Table 82. Eagle Pharmaceuticals Recent Development
Table 83. Merrimack Pharmaceuticals Company Detail
Table 84. Merrimack Pharmaceuticals Business Overview
Table 85. Merrimack Pharmaceuticals HR+HER2- Breast Cancer Product
Table 86. Merrimack Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2017-2022) & (US$ Million)
Table 87. Merrimack Pharmaceuticals Recent Development
Table 88. GlaxoSmithKline Company Detail
Table 89. GlaxoSmithKline Business Overview
Table 90. GlaxoSmithKline HR+HER2- Breast Cancer Product
Table 91. GlaxoSmithKline Revenue in HR+HER2- Breast Cancer Business (2017-2022) & (US$ Million)
Table 92. GlaxoSmithKline Recent Development
Table 93. Millennium Pharmaceuticals Company Detail
Table 94. Millennium Pharmaceuticals Business Overview
Table 95. Millennium Pharmaceuticals HR+HER2- Breast CancerProduct
Table 96. Millennium Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2017-2022) & (US$ Million)
Table 97. Millennium Pharmaceuticals Recent Development
Table 98. Bayer Company Detail
Table 99. Bayer Business Overview
Table 100. Bayer HR+HER2- Breast CancerProduct
Table 101. Bayer Revenue in HR+HER2- Breast Cancer Business (2017-2022) & (US$ Million)
Table 102. Bayer Recent Development
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
List of FiguresFigure 1. Global HR+HER2- Breast Cancer Market Share by Type: 2021 VS 2028
Figure 2. CDK4/6 Inhibitors Features
Figure 3. PARP Inhibitors Features
Figure 4. PI3K Inhibitor Features
Figure 5. Others Features
Figure 6. Global HR+HER2- Breast Cancer Market Share by Application in 2021 & 2028
Figure 7. Hospitals Case Studies
Figure 8. Cancer Center Case Studies
Figure 9. Medical Research and Academic Institutions Case Studies
Figure 10. Ambulatory Surgical Centers Case Studies
Figure 11. Others Case Studies
Figure 12. HR+HER2- Breast Cancer Report Years Considered
Figure 13. Global HR+HER2- Breast Cancer Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 14. Global HR+HER2- Breast Cancer Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 15. Global HR+HER2- Breast Cancer Market Share by Region: 2021 VS 2028
Figure 16. Global HR+HER2- Breast Cancer Market Share by Players in 2021
Figure 17. Global Top HR+HER2- Breast Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HR+HER2- Breast Cancer as of 2021)
Figure 18. The Top 10 and 5 Players Market Share by HR+HER2- Breast Cancer Revenue in 2021
Figure 19. North America HR+HER2- Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. North America HR+HER2- Breast Cancer Market Share by Country (2017-2028)
Figure 21. United States HR+HER2- Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. Canada HR+HER2- Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Europe HR+HER2- Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Europe HR+HER2- Breast Cancer Market Share by Country (2017-2028)
Figure 25. Germany HR+HER2- Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. France HR+HER2- Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. U.K. HR+HER2- Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Italy HR+HER2- Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Russia HR+HER2- Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Nordic Countries HR+HER2- Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Asia-Pacific HR+HER2- Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Asia-Pacific HR+HER2- Breast Cancer Market Share by Region (2017-2028)
Figure 33. China HR+HER2- Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Japan HR+HER2- Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. South Korea HR+HER2- Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Southeast Asia HR+HER2- Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. India HR+HER2- Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Australia HR+HER2- Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Latin America HR+HER2- Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Latin America HR+HER2- Breast Cancer Market Share by Country (2017-2028)
Figure 41. Mexico HR+HER2- Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Brazil HR+HER2- Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Middle East & Africa HR+HER2- Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Middle East & Africa HR+HER2- Breast Cancer Market Share by Country (2017-2028)
Figure 45. Turkey HR+HER2- Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 46. Saudi Arabia HR+HER2- Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Jiangsu HengRui Medicine Revenue Growth Rate in HR+HER2- Breast Cancer Business (2017-2022)
Figure 48. Odonate Therapeutics Revenue Growth Rate in HR+HER2- Breast Cancer Business (2017-2022)
Figure 49. Radius Pharmaceuticals Revenue Growth Rate in HR+HER2- Breast Cancer Business (2017-2022)
Figure 50. Immunomedics Revenue Growth Rate in HR+HER2- Breast Cancer Business (2017-2022)
Figure 51. Roche Group Revenue Growth Rate in HR+HER2- Breast Cancer Business (2017-2022)
Figure 52. Syndax Pharmaceuticals Revenue Growth Rate in HR+HER2- Breast Cancer Business (2017-2022)
Figure 53. Merck Revenue Growth Rate in HR+HER2- Breast Cancer Business (2017-2022)
Figure 54. Eagle Pharmaceuticals Revenue Growth Rate in HR+HER2- Breast Cancer Business (2017-2022)
Figure 55. Merrimack Pharmaceuticals Revenue Growth Rate in HR+HER2- Breast Cancer Business (2017-2022)
Figure 56. GlaxoSmithKline Revenue Growth Rate in HR+HER2- Breast Cancer Business (2017-2022)
Figure 57. Millennium Pharmaceuticals Revenue Growth Rate in HR+HER2- Breast Cancer Business (2017-2022)
Figure 58. Bayer Revenue Growth Rate in HR+HER2- Breast Cancer Business (2017-2022)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed